Barclays raised the firm’s price target on Kodiak Sciences to $3 from $2 and keeps an Underweight rating on the shares. The company’s Q4 report highlighted manufacturing progress and pivotal trial development plans across key pipeline programs, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
